DIMERIX INVESTOR CALL & PRESENTATION
Two Phase 3 studies in COVID-19 patients
Patients were randomised patients to receive one of:
1.
2.
Angiotensin receptor blocker (ARB) alone
Angiotensin converting enzyme (ACE) inhibitor alone
ARB simultaneously with DMX-200
No RAS inhibitor (no placebo)
3.
REMAP CAP 4.
J
NHMRC
Clinical Trials Centre
BB
THE UNIVERSITY OF
SYDNEY
.
REMAP-CAP: COVID-19 pneumonia in ICU
>779 patients recruited to the study domain
WHO endorsed study
Primary endpoint = 21 day mortality
Funded by European Union through H2020
"Rapid European COVID-19 Emergency
Research response" (RECOVER) project
CLARITY 2.0: COVID-19 respiratory complications
Recruiting >600 patients in India and Australia
Primary endpoint = 14 day WHO Clinical Health Score
Run through the NHMRC Clinical trials centre and the University
of Sydney
Dimerix
Secondary endpoint: recovery and quality of life
post hospitalisation (long-COVID assessment)
Initial study data anticipated Q1 2022
8View entire presentation